```
$%^STN:HighlightOn=  ***;HighlightOff=***  ;
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1604dxj
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06  Engineering Information Encompass files have new names
 NEWS  4  Feb 16  TOXLINE no longer being updated
 NEWS  5  Apr 23  Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23  PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07  DGENE Reload

 NEWS EXPRESS  May 23 CURRENT WINDOWS VERSION IS V6.0a,
               CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
               AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:24:52 ON 12 JUN 2001

=> file reg

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.15       0.15

FILE 'REGISTRY' ENTERED AT 12:25:07 ON 12 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   10 JUN 2001  HIGHEST RN 340232-86-2
DICTIONARY FILE UPDATES:  10 JUN 2001  HIGHEST RN 340232-86-2

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
for details.

=> s amiodarone/cn

L1            1 AMIODARONE/CN

=> d l1


L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2001 ACS
RN   1951-25-3  REGISTRY
```

```
CN   Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-
     diiodophenyl]- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl
     (7CI, 8CI)
OTHER NAMES:
CN   2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone
CN   2-Butyl-3-[3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl]benzofuran
CN   2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
CN     ***Amiodarone***
CN   Sedacoron
CN   Sedacorone
FS   3D CONCORD
MF   C25 H29 I2 N O3
CI   COM
LC   STN Files:   AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
       CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
       DRUGUPDATES, EMBASE, HSDB*, IMSDIRECTORY, IPA, MEDLINE, MRCK*, NIOSHTIC,
       PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)


/ Structure 1 in file .gra /

            1225 REFERENCES IN FILE CA (1967 TO DATE)
              17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            1225 REFERENCES IN FILE CAPLUS (1967 TO DATE)
               5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s dronedarone/cn

L2            1 DRONEDARONE/CN

=> d l2


L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2001 ACS
RN   141626-36-0  REGISTRY
CN   Methanesulfonamide, N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-
     benzofuranyl]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN     ***Dronedarone***
CN   SR 33589
FS   3D CONCORD
MF   C31 H44 N2 O5 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, BIOSIS, CA, CAPLUS, DDFU, DRUGNL, DRUGU,
       DRUGUPDATES, EMBASE, PROMT, TOXLIT, USAN, USPATFULL
     Other Sources:   WHO


/ Structure 2 in file .gra /

              20 REFERENCES IN FILE CA (1967 TO DATE)
               2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              20 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> file medline, embase, embal, ca, caplus, biosis'

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                11.22      11.37

FILE 'MEDLINE' ENTERED AT 12:26:09 ON 12 JUN 2001
```

FILE 'EMBASE' ENTERED AT 12:26:09 ON 12 JUN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'EMBAL' ENTERED AT 12:26:09 ON 12 JUN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'CA' ENTERED AT 12:26:09 ON 12 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 12:26:09 ON 12 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:26:09 ON 12 JUN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

=> s l1 or l2

'CN' IS NOT A VALID FIELD CODE
L3 21282 L1 OR L2

=> s cordarone or amiodarone or benzofuran or dronedarone

L4 37729 CORDARONE OR AMIODARONE OR BENZOFURAN OR DRONEDARONE

=> s l3 or l4

L5 37780 L3 OR L4

=> s anionic surfactant

L6 22946 ANIONIC SURFACTANT

=> s poloxamer? or polyethyoxylated castor oil? or ethoxylated polysorbate? or polyethylene hydr

L7 45179 POLOXAMER? OR POLYETHYOXYLATED CASTOR OIL? OR ETHOXYLATED POLYSO
RBATE? OR POLYETHYLENE HYDROXYSTEARATE? OR TWEEN? OR CREMOPHOR
OR SOLUTROL

=> s l5 and l7

L8 66 L5 AND L7

=> dup rem

ENTER L# LIST OR (END):l8

PROCESSING COMPLETED FOR L8
L9 33 DUP REM L8 (33 DUPLICATES REMOVED)

=> s oral or tablet or capsule or gelatin or pill

L10 1486690 ORAL OR TABLET OR CAPSULE OR GELATIN OR PILL

=> s l9 and l10

L11 4 L9 AND L10

=> d l11 1-4 bib, ab, kwic

L11 ANSWER 1 OF 4 MEDLINE
AN 91346480 MEDLINE
DN 91346480 PubMed ID: 2102806
TI Hemodynamic profile of ***amiodarone*** during acute and long-term
administration in patients with ventricular dysfunction.
AU Remme W J; van Hoogenhuyze D C
CS Cardiovascular Research Foundation Sticares, Rotterdam, The Netherlands.

SO CARDIOSCIENCE, (1990 Sep) 1 (3) 169-76. Ref: 19
Journal code: A5U; 9014943. ISSN: 1015-5007.
CY Italy
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199110
ED Entered STN: 19911020
Last Updated on STN: 19911020
Entered Medline: 19911003
AB One of the potential adverse effects of anti-arrhythmic agents is an impairment of cardiac function as a result of their intrinsic negative inotropic properties. ***Amiodarone*** , in animals, also induces dose-related negative inotropic effects, in addition to coronary and systemic vasodilatation and slowing of the heart. Likewise, in most human studies, intravenous ***amiodarone*** gives rise to early systemic and coronary vasodilatation, followed by a reduction in contractility. Depending on the relative impact of these opposing effects on the left ventricle, the changes in heart rate, cardiac output and left ventricular filling pressure are variable. Particularly in patients with pre-existing ventricular dysfunction, cardiac pump function is impaired further when relatively high dosages of ***amiodarone*** are used without its solvent ***Tween*** 80. In contrast, fast bolus administrations, eg. 5 mg/kg ***amiodarone*** in 5 minutes, result in an improvement of cardiac output, albeit at the expense of an increase in left ventricular filling pressure. The latter observation suggests that intravenous ***amiodarone*** should be given with caution in patients with heart failure and elevated left ventricular filling pressures. When given by mouth, ***amiodarone*** does not have significant hemodynamic effects, other than a moderate reduction in heart rate and, occasionally, in diastolic blood pressure. Cardiac pump function is not affected, even in patients with ventricular dysfunction or heart failure, in whom chronic ***oral*** administration of the drug is well tolerated.
TI Hemodynamic profile of ***amiodarone*** during acute and long-term administration in patients with ventricular dysfunction.
AB . . . adverse effects of anti-arrhythmic agents is an impairment of cardiac function as a result of their intrinsic negative inotropic properties. ***Amiodarone*** , in animals, also induces dose-related negative inotropic effects, in addition to coronary and systemic vasodilatation and slowing of the heart. Likewise, in most human studies, intravenous ***amiodarone*** gives rise to early systemic and coronary vasodilatation, followed by a reduction in contractility. Depending on the relative impact of. . . are variable. Particularly in patients with pre-existing ventricular dysfunction, cardiac pump function is impaired further when relatively high dosages of ***amiodarone*** are used without its solvent ***Tween*** 80. In contrast, fast bolus administrations, eg. 5 mg/kg ***amiodarone*** in 5 minutes, result in an improvement of cardiac output, albeit at the expense of an increase in left ventricular filling pressure. The latter observation suggests that intravenous ***amiodarone*** should be given with caution in patients with heart failure and elevated left ventricular filling pressures. When given by mouth, ***amiodarone*** does not have significant hemodynamic effects, other than a moderate reduction in heart rate and, occasionally, in diastolic blood pressure. Cardiac pump function is not affected, even in patients with ventricular dysfunction or heart failure, in whom chronic ***oral*** administration of the drug is well tolerated.
CT Check Tags: Animal; Human
*** Amiodarone: AD, administration & dosage***
*** Amiodarone: AE, adverse effects***
****Amiodarone: TU, therapeutic use***
*Arrhythmia: DT, drug therapy
Dose-Response Relationship, Drug
Heart Failure, Congestive: PP, physiopathology
*Hemodynamics: DE, drug effects
Myocardial. . .
RN ***1951-25-3 (Amiodarone)***

L11 ANSWER 2 OF 4 CA COPYRIGHT 2001 ACS
AN 134:32972 CA
TI Porous drug matrixes containing polymers and sugars and methods of their

manufacture
IN Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
PA Acusphere, Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000072827	A2	20001207	WO 2000-US14578	20000525
WO 2000072827	A3	20010125		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI	US 1999-136323	P	19990527
	US 1999-158659	P	19991008
	US 1999-433486	A	19991104
	US 2000-186310	P	20000302

AB Drugs, esp. low aq. soly. drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aq. media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aq. soly., in a volatile solvent to form a drug soln., (ii) combining at least one pore forming agent with the drug soln. to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second soln. to yield the porous matrix of drug. The pore forming agent can be either a volatile liq. that is immiscible with the drug solvent or a volatile solid compd., preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aq. medium and administered parenterally, or processed using std. techniques into tablets or capsules for ***oral*** administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. For example, a nifedipine-loaded org. soln. was prepd. by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aq. soln. was prepd. by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aq. and org. solns. were homogenized and resulting emulsion was spray dried. A suspension of the porous nifedipine drug matrix was prepd. in 5% dextrose soln. at a concn. of 2.5 mg/mL. A bolus injection of the suspension was tolerated when administrated to dogs.
AB Drugs, esp. low aq. soly. drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aq. media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aq. soly., in a volatile solvent to form a drug soln., (ii) combining at least one pore forming agent with the drug soln. to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second soln. to yield the porous matrix of drug. The pore forming agent can be either a volatile liq. that is immiscible with the drug solvent or a volatile solid compd., preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aq. medium and administered parenterally, or processed using std. techniques into tablets or capsules for ***oral*** administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing

agents and administered as a bolus. For example, a nifedipine-loaded org. soln. was prepd. by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aq. soln. was prepd. by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aq. and org. solns. were homogenized and resulting emulsion was spray dried. A suspension of the porous nifedipine drug matrix was prepd. in 5% dextrose soln. at a concn. of 2.5 mg/mL. A bolus injection of the suspension was tolerated when administrated to dogs.

ST drug solubilization polymer sugar porous matrix; microparticle ***oral*** parenteral drug porous matrix

IT Drug delivery systems
(***oral*** ; prepn. of porous matrixes contg. hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-99-7, Dextrose, biological studies 52-53-9, Verapamil 53-03-2, Prednisone 55-98-1, Busulfan 57-63-6, Ethinyl estradiol 58-61-7, Adenosine, biological studies 59-92-7, Levodopa, biological studies 67-78-7 67-97-0, Vitamin D3 67-97-0D, Vitamin D3, analogs 71-58-9, Medroxyprogesterone acetate 75-64-9, Erbumine, biological studies 77-36-1, Chlorthalidone 89-57-6, Mesalamine 126-07-8, Griseofulvin 128-13-2, Ursodiol 298-46-4, Carbamazepine 302-79-4, Tretinoin 321-64-2, Tacrine 363-24-6, Dinoprostone 437-38-7, Fentanyl 439-14-5, Diazepam 443-48-1, Metronidazole 518-28-5, Podofilox 745-65-3, Alprostadil 846-49-1, Lorazepam ***1951-25-3*** , ***Amiodarone*** 3239-44-9, Dexfenfluramine 4759-48-2, Isotretinoin 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 9002-68-0, Follitropin 9002-72-6, Growth hormone 9005-49-6, Enoxaparin, biological studies 9007-12-9, Calcitonin 9041-93-4, Bleomycin sulfate 10238-21-8, Glyburide 11096-26-7, Erythropoietin 12629-01-5, Somatropin 12633-72-6, Amphotericin 13311-84-7, Flutamide 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 18559-94-9, Albuterol 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22204-53-1, Naproxen 27203-92-5, Tramadol 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29094-61-9, Glipizide 30516-87-1, Zidovudine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 34911-55-2, Bupropion 36505-84-7, Buspirone 40391-99-9 41340-25-4, Etodolac 41575-94-4, Carboplatin 42399-41-7, Diltiazem 42924-53-8, Nabumetone 51022-70-9, Albuterol sulfate 51333-22-3, Budesonide 51773-92-3, Mefloquine hydrochloride 54143-55-4, Flecainide 54527-84-3, Nicardipine hydrochloride 54910-89-3, Fluoxetine 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-75-2, Cefuroxime 56124-62-0, Valrubicin 56180-94-0, Acarbose 59729-33-8, Citalopram 60142-96-3, Gabapentin 60205-81-4, Ipratropium 63659-18-7, Betaxolol 65277-42-1, Ketoconazole 66085-59-4, Nimodipine 66376-36-1, Alendronate 66852-54-8, Halobetasol propionate 69655-05-6, Didanosine 70476-82-3, Mitoxantrone hydrochloride 72432-03-2, Miglitol 72509-76-3, Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol 73384-59-5, Ceftriaxone 73590-58-6, Omeprazole 75330-75-5, Lovastatin 75695-93-1, Isradipine 75847-73-3, Enalapril 76095-16-4, Enalapril maleate 76547-98-3, Lisinopril 76824-35-6, Famotidine 76963-41-2, Nizatidine 77883-43-3, Doxazosin mesylate 78246-49-8, Paroxetine hydrochloride 78628-80-5, Terbinafine hydrochloride 78755-81-4, Flumazenil 79517-01-4, Octreotide acetate 79559-97-0, Sertraline hydrochloride 79794-75-5, Loratadine 79902-63-9, Simvastatin 80274-67-5, Metoprolol fumarate 81098-60-4, Cisapride 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82752-99-6, Nefazodone hydrochloride 82834-16-0, Perindopril 83799-24-0, Fexofenadine 83905-01-5, Azithromycin 83919-23-7, Mometasone furoate 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86541-74-4, Benazepril hydrochloride 86541-75-5, Benazepril 87679-37-6, Trandolapril 89778-27-8, Toremifene citrate 91161-71-6, Terbinafine 91421-42-0, Rubitecan 93413-69-5, Venlafaxine 93957-54-1, Fluvastatin 95058-81-4, Gemcitabine 95233-18-4, Atovaquone 97048-13-0, Urofollitropin 97322-87-7, Troglitazone 98048-97-6, Fosinopril 98079-52-8, Lomefloxacin hydrochloride 98319-26-7, Finasteride 99011-02-6, Imiquimod 99294-93-6, Zolpidem tartrate 100286-90-6, Irinotecan hydrochloride 100986-85-4, Levofloxacin 103577-45-3, Lansoprazole 103628-48-4, Sumatriptan succinate 103775-10-6, Moexipril 104227-87-4, Famciclovir 104632-25-9, Pramipexole dihydrochloride 106266-06-2, Risperidone 106463-17-6, Tamsulosin hydrochloride 106685-40-9, Adapalene 107753-78-6, Zafirlukast 109889-09-0,

Granisetron 110871-86-8, Sparfloxacin 111470-99-6, Amlodipine besylate 111974-72-2, Quetiapine fumarate 112809-51-5, Letrozole 113806-05-6, Olopatadine 114798-26-4, Losartan 114977-28-5, Docetaxel 115956-12-2, Dolasetron 12Q014-06-4, Donepezil 124832-26-4, Valacyclovir 127779-20-8, Saquinavir 131918-61-1, Paricalcitol 132539-06-1, Olanzapine 134308-13-7, Tolcapone 134678-17-4, Lamivudine 137862-53-4, Valsartan 140678-14-4, Mangafodipir trisodium 142373-60-2, Tirofiban hydrochloride 143011-72-7, Granulocyte colony-stimulating factor 144701-48-4, Telmisartan 145040-37-5, Candesartan cilexetil 147059-72-1, Trovafloxacin 147245-92-9, Glatiramer acetate 150378-17-9, Indinavir 154248-97-2, Imiglucerase 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate 155213-67-5, Ritonavir 158966-92-8, Montelukast 159989-65-8, Nelfinavir mesylate 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 171599-83-0, Sildenafil citrate
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prepn. of porous matrixes contg. hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT 64-17-5, Ethanol, biological studies 9003-43-4, Polyvinylpyrrolidine 9005-65-6, ***Tween*** 80 25322-68-3, Polyethylene glycol 26266-57-9, Span 40 106392-12-5, Pluronic F127 211733-74-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of porous matrixes contg. hydrophilic polymers and sugars for enhancement of drug dissoln.)

L11 ANSWER 3 OF 4 CA COPYRIGHT 2001 ACS
AN 133:301171 CA
TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IN Chen, Feng-jing; Patel, Manesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-287043 A 19990406
AB The present invention is directed to a pharmaceutical compn. including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of prepg. such compns. by providing a compn. of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in ***oral*** dosage forms. A carrier contg. concd. phosphoric acid 0.025, ***Tween*** -20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole soln. upon diln. in simulated gastric fluid.
RE.CNT 3
RE
(1) Blair; US 4306981 A 1981 CA
(2) Hauer; US 5342625 A 1994 CA
(3) Story; US 4944949 A 1990 CA
AB The present invention is directed to a pharmaceutical compn. including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of

ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of prepg. such compns. by providing a compn. of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in ***oral*** dosage forms. A carrier contg. concd. phosphoric acid 0.025, ***Tween*** -20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole soln. upon diln. in simulated gastric fluid.

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated, ***Cremophor*** RH 40; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Drug delivery systems
(***oral*** ; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Drug delivery systems
(solns., ***oral*** ; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 50-06-6, Phenobarbital, biological studies 50-21-5, biological studies 50-21-5D, Lactic acid, glycerides 50-44-2, Mercaptopurine 50-48-6, Amitriptyline 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-78-2 50-81-7, Ascorbic acid, biological studies 51-48-9, Levothyroxine, biological studies 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-64-9, Dexamphetamine 52-86-8, Haloperidol 53-86-1, Indomethacin 54-05-7, Chloroquine 54-11-5, Nicotine 54-31-9 56-54-2, Quinidine 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-22-7, Vincristine 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-43-2, Amylobarbital 57-44-3, Barbital 57-47-6, Physostigmine 57-66-9, Probenecid 57-88-5, Cholesterol, biological studies 58-14-0, Pyrimethamine 58-25-3, Chlordiazepoxide 58-32-2, Dipyridamole 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-73-1, Diphenhydramine 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-66-5, Acetazolamide 59-87-0, Nitrofurazone 59-96-1, Phenoxybenzamine 61-56-3, Sulthiame 61-68-7, Mefenamic acid 61-72-3, Cloxacillin 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-77-7, Tolbutamide 65-85-0, Benzoic acid, biological studies 66-76-2, Dicumarol 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 68-04-2, Sodium Citrate 68-11-1, Thioglycolic acid, biological studies 68-35-9, Sulfadiazine 69-23-8, Fluphenazine 69-72-7, biological studies 69-93-2, Uric acid, biological studies 72-44-6, Methaqualone 72-69-5, Nortriptyline 74-55-5, Ethambutol 75-75-2, Methanesulfonic acid 76-57-3, Codeine 76-74-4, Pentobarbital 76-99-3, Methadone 77-28-1, Butobarbital 77-36-1, Chlorthalidone 77-86-1, Tromethamine 77-92-9, biological studies 79-09-4, Propanoic acid, biological studies 79-10-7, Acrylic acid, biological studies 82-92-8, Cyclizine 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-89-6, Mepacrine 86-21-5, Pheniramine 86-22-6, Brompheniramine 86-35-1, Ethotoin 86-42-0, Amodiaquine 87-69-4 89-57-6, Mesalamine 89-65-6, Isoascorbic acid 90-82-4, Pseudoephedrine 90-84-6, Diethylpropion 94-20-2, Chlorpropamide 97-23-4, Dichlorophen 99-66-1, Valproic acid 101-31-5, Hyoscyamine 102-71-6, biological studies 104-15-4, p-Toluenesulfonic acid, biological studies 107-15-3, 1,2-Ethanediamine, biological studies 107-92-6, Butyric acid, biological studies 110-15-6, Butanedioic acid, biological studies 110-16-7, 2-Butenedioic acid (2Z)-, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Ethyl Oleate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 113-15-5, Ergotamine 113-45-1, Methylphenidate 113-59-7, Chlorprothixene 113-92-8 114-07-8, Erythromycin 115-38-8, Methylphenobarbital 117-89-5, Trifluoperazine 121-44-8, biological studies 122-09-8, Phentermine 122-20-3, Triisopropanolamine 124-04-9, Hexanedioic acid, biological studies 125-28-0, Dihydrocodeine 125-53-1, Oxyphencyclimine 125-84-8, Aminoglutethimide 127-09-3, Sodium Acetate 127-33-3, Demeclocycline 127-69-5, Sulfafurazole

127-71-9, Sulfabenzamide 127-79-7, Sulfamerazine 128-13-2, Ursodeoxycholic acid 128-37-0, Butylated Hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxyphenbutazone 130-95-0, Quinine 132-17-2, Benztropine 138-36-3, p-Bromophenylsulfonic acid 139-33-3, Edetate Disodium 141-43-5, biological studies 142-18-7, Glyceryl monolaurate 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 144-11-6, Benzhexol 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Ethanedioic acid, biological studies 144-80-9, Sulfacetamide 144-83-2, Sulfapyridine 145-42-6, Taurocholic acid, sodium salt 146-22-5, Nitrazepam 146-54-3, Fluopromazine 148-79-8, Thiabendazole 151-21-3, Sodium Dodecyl Sulfate, biological studies 154-42-7, Thioguanine 190-39-6, Bisanthene 288-14-2, Isoxazole 298-57-7, Cinnarizine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-79-4, Tretinoin 305-03-3, Chlorambucil 321-64-2, Tacrine 359-83-1, Pentazocine 361-37-5, Methysergide 364-62-5, Metoclopramide 389-08-2 396-01-0, Triamterene 404-86-4, Capsaicin 437-38-7, Fentanyl 439-14-5, Diazepam 442-52-4, Clemizole 443-48-1, Metronidazole 446-86-6, Azathioprine 458-24-2, Fenfluramine 463-79-6, Carbonic acid, biological studies 471-34-1, Calcium carbonate, biological studies 486-16-8, Carbinoxamine 500-92-5, Proguanil 511-12-6, Dihydroergotamine 514-65-8, Biperiden 519-23-3, Ellipticine 522-00-9, Ethopropazine 523-87-5, Dimenhydrinate 525-66-6 526-95-4, D-Gluconic acid 536-33-4, Ethionamide 537-21-3, Chlorproguanil 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 548-73-2, Droperidol 561-27-3, Diamorphine 564-25-0, Doxycycline 569-65-3, Meclozine 577-11-7, Docusate sodium 599-79-1, Sulfasalazine 603-50-9, Bisacodyl 604-75-1, Oxazepam 631-61-8, Ammonium Acetate 644-62-2, Meclofenamic acid 657-24-9, Metformin 668-94-0, 4,5-Diphenylimidazole 671-16-9, Procarbazine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 739-71-9, Trimipramine 745-65-3, Alprostadil 768-94-5, Amantadine 846-49-1, Lorazepam 846-50-4, Temazepam 848-75-9, Lormetazepam 865-21-4, Vinblastine 911-45-5, Clomiphene 915-30-0, Diphenoxylate 961-71-7, Phenbenzamine 968-81-0, Acetohexamide 1134-47-0, Baclofen 1156-19-0, Tolazamide 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium Hydroxide, biological studies 1310-73-2, Sodium Hydroxide, biological studies 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene glycol oleate 1333-28-4, Undecenoic acid 1335-30-4, Aluminum silicate 1336-21-6, Ammonium Hydroxide 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1400-61-9, Nystatin 1404-90-6, Vancomycin 1406-05-9, Penicillins 1508-75-4, Tropicamide 1553-60-2, Ibufenac 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1812-30-2, Bromazepam ***1951-25-3*** , ***Amiodarone*** 1972-08-3, Dronabinol 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2078-54-8, Propofol 2447-57-6, Sulfadoxine 2487-39-0, Vitamin K-S (II) 2515-61-9, 1,5-Diphenylpyrazoline 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 2998-57-4, Estramustine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3239-44-9, Dexfenfluramine 3737-09-5, Disopyramide 4117-33-3, Lysine Ethyl Ester 4342-03-4, Dacarbazine 4759-48-2, Isotretinoin 5002-47-1, Fluphenazine decanoate 5036-02-2, Tetramisole 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl Isosorbide 5588-33-0, Mesoridazine 5633-20-5, Oxybutynin 5786-21-0, Clozapine 6452-71-7, Oxprenolol 6493-05-6, Pentoxifylline 6506-37-2, Nimorazole 7087-68-5, Diisopropylethylamine 7261-97-4, Dantrolene 7416-34-4, Molindone 7647-01-0, Hydrochloric Acid, biological studies 7664-38-2, Phosphoric acid, biological studies 7664-38-2D, Phosphoric acid, esters 7664-93-9, Sulfuric acid, biological studies 7681-93-8, Natamycin 7689-03-4, Camptothecin 7697-37-2, Nitric acid, biological studies 7778-53-2, Potassium Phosphate 8007-43-0, Sorbitan sesquioleate 8045-34-9, Pentaerythritol stearate 9002-92-0, Polyoxyethylene lauryl ether 9002-93-1 9002-96-4, D-.alpha.-Tocopheryl polyethylene glycol succinate 9004-74-4, Methoxy polyethylene glycol 9004-95-9, Polyethylene glycol cetyl ether 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Myrj 51 9005-00-9, Polyoxyethylene stearyl ether 9005-08-7, Polyethylene glycol distearate 9005-32-7, Alginic acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, ***Tween*** 40 9005-67-8, ***Tween*** 60 9007-48-1, Polyglyceryl oleate 9011-21-6

9011-29-4 9014-67-9, Aloxiprin 9016-45-9 9062-73-1, Polyethylene glycol sorbitan laurate 9062-90-2, Polyethylene glycol sorbitan oleate 10034-85-2, Hydriodic acid 10035-10-6, Hydrobromic acid, biological studies 10043-35-3, Boric acid, biological studies 10238-21-8 10262-69-8, Maprotiline 10457-90-6, Bromperidol 10540-29-1, Tamoxifen 11140-04-8, Imwitor 988 12633-72-6, Amphotericin 12772-47-3, Pentaerythritol oleate 13292-46-1, Rifampin 13392-28-4, Rimantadine 13523-86-9 13655-52-2, Alprenolol 14028-44-5, Amoxapine 14611-51-9, Selegiline 14808-79-8, Sulfate, biological studies 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalexin 15686-83-6, Pyrantel 15687-27-1, Ibuprofen 16110-51-3, Cromoglicic acid 16773-42-5, Ornidazole 17560-51-9, Metolazone 17617-23-1, Flurazepam 18016-80-3, Lysuride 18507-89-6, Decoquinate 18559-94-9, Albuterol 19216-56-9, Prazosin 19387-91-8, Tinidazole 19794-93-5, Trazodone 20594-83-6, Nalbuphine 21187-98-4, Gliclazide 21256-18-8, Oxaprozin 21645-51-2, Aluminum hydroxide, biological studies 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22131-79-9, Alclofenac 22204-53-1 22232-71-9, Mazindol 22494-42-4, Diflunisal 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 22994-85-0, Benznidazole 23031-25-6, Terbutaline 23110-15-8, Fumagillin 23288-49-5, Probucol 23593-75-1, Clotrimazole 24219-97-4, Mianserin 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine. 25614-03-3, Bromocriptine 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26097-80-3, Cambendazole 26171-23-3, Tolmetin 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate 26839-75-8, Timolol 26912-41-4D, Polyethylene glycol caprate, glycerides 27195-16-0, Sucrose distearate 27203-92-5, Tramadol 27220-47-9, Econazole 27321-96-6, Polyethylene glycol cholesterol 27638-00-2, Glyceryl dilaurate 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9, Glipizide 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29767-20-2, Teniposide 30299-08-2, Clinofibrate 30909-51-4, Flupentixol decanoate 31431-39-7, Mebendazole 31692-85-0, Glycofurol 33419-42-0, Etoposide 33671-46-4, Clotiazepam 33940-98-6 34406-66-1, Nikkol Decaglyn 1L 34580-13-7, Ketotifen 34911-55-2, Bupropion 36322-90-4, Piroxicam 36330-85-5, Fenbufen 36354-80-0, Glyceryl dicaprylate 36531-26-7, Oxantel 36894-69-6, Labetalol 37148-27-9, Clenbuterol 37220-82-9, ARLACEL 186 37318-31-3, Crodesta F-160 37321-62-3, Lauroglycol FCC 37517-30-9, Acebutolol 38194-50-2, Sulindac 38304-91-5, Minoxidil 38821-53-3, Cephradine 39366-43-3, Magnesium aluminum hydroxide 41340-25-4, Etodolac 41859-67-0, Bezafibrate 42200-33-9, Nadolol 42399-41-7, Diltiazem 42766-91-6, Nikkol DHC 43200-80-2, Zopiclone 43210-67-9, Fenbendazole 50679-08-8, Terfenadine 51192-09-7, Nikkol TMGO 5 51264-14-3, Amsacrine 51322-75-9, Tizanidine 51384-51-1, Metoprolol 51481-61-9, Cimetidine 51803-78-2 51938-44-4, Sorbitan sesquistearate 52081-33-1, Mitomycins 52468-60-7, Flunarizine 52504-24-2, Softigen 767 52581-71-2, Volpo 3 52942-31-1, Etoperidone 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53716-50-0, Oxfendazole 53988-07-1, Glyceryl dicaprate 54029-12-8, Ricobendazole 54143-55-4, Flecainide 54340-58-8, Meptazinol 54392-26-6, Sorbitan monoisostearate 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55268-74-1, Praziquantel 55985-32-5, Nicardipine 57107-95-6 57307-93-4, Pentaerythritol caprylate 57801-81-7, Brotizolam 57808-66-9, Domperidone 58581-89-8, Azelastine 59467-70-8, Midazolam 59729-33-8, Citalopram 60142-96-3, Gabapentin 60607-34-3, Oxatomide 60719-84-8, Amrinone 61318-90-9, Sulconazole 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62571-86-2, Captopril 63590-64-7, Terazosin 63675-72-9, Nisoldipine 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64840-90-0, Eperisone 64872-76-0, Butoconazole 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65899-73-2, Tioconazole 66085-59-4, Nimodipine 66357-35-5, Ranitidine 67227-56-9, Fenoldopam 67352-02-7 67915-31-5, Terconazole 68506-86-5, Vigabatrin 68844-77-9, Astemizole 68958-64-5, Polyethylene glycol glyceryl trioleate 68993-42-0D, Polyethylene glycol caprylate, glycerides 69070-98-0 69756-53-2, Halofantrine 70458-96-7, Norfloxacin 71125-38-7, Meloxicam 71486-22-1, Vinorelbine 72432-03-2, Miglitol 72509-76-3, Felodipine 72559-06-9, Rifabutin 72803-02-2, Darodipine 73590-58-6, Omeprazole 74011-58-8, Enoxacin

74103-06-3, Ketorolac 74191-85-8, Doxazosin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

L11 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS
AN 133:286507 CA
TI Formulation arrays for screening
IN Galakatos, Nicholas; Langer, Robert S.; Putnam, David A.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059627	A1	20001012	WO 2000-US8589	20000331

PI
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-127755 P 19990405
US 1999-146019 P 19990728

AB Methods are described for high throughput combinatorial formulation in combination with nanotechnol. and microarrays to improve properties of materials used as components of, or in the manuf. or use of, health care products, consumer products, agricultural products, nutraceutical products, veterinary products, products for use in manufg. or processing industries, military applications, and research reagents. In particular, the bioavailability and pharmacokinetics of drugs, esp. small mol. pharmaceuticals, are optimized by making many new formulations and selecting those formulations based on phys. or chem. properties such as soly. in an aq. soln., without compromising selectivity or potency. Systems employing these technologies are described for rapid, systematic and cheap identification of optimal compns. for a desired purpose. New formulations can be prepd. and tested for bioequivalence to a formulation that is approved or com. available. Addnl., formulations can be initially optimized in vitro for their pharmacokinetics, such as absorption through the gut (for an ***oral*** prepn.), skin (for transdermal application), or mucosa (for nasal, buccal, vaginal or rectal formulation), soly., degrdn. or clearance by uptake into the reticuloendothelial system ("RES"), metab. or elimination, then tested in vivo.

RE.CNT 9
RE
(2) Gold, G; JOURNAL OF PHARMACEUTICAL SCIENCES 1964, V53(1), P52 CA
(4) McFarland, E; TRENDS IN BIOTECHNOLOGY 1999, V17(3), P107 CA
(5) Pokorny, V; WO 9840159 A 1998 CA
(6) Rothbard, J; WO 9852614 A 1998 CA
(8) Song, C; JOURNAL OF CONTROLLED RELEASE 1997, V45(2), P177 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Methods are described for high throughput combinatorial formulation in combination with nanotechnol. and microarrays to improve properties of materials used as components of, or in the manuf. or use of, health care products, consumer products, agricultural products, nutraceutical products, veterinary products, products for use in manufg. or processing industries, military applications, and research reagents. In particular, the bioavailability and pharmacokinetics of drugs, esp. small mol. pharmaceuticals, are optimized by making many new formulations and selecting those formulations based on phys. or chem. properties such as soly. in an aq. soln., without compromising selectivity or potency. Systems employing these technologies are described for rapid, systematic and cheap identification of optimal compns. for a desired purpose. New formulations can be prepd. and tested for bioequivalence to a formulation that is approved or com. available. Addnl., formulations can be initially optimized in vitro for their pharmacokinetics, such as absorption through

the gut (for an ***oral*** prepn.), skin (for transdermal application), or mucosa (for nasal, buccal, vaginal or rectal formulation), soly., degrdn. or clearance by uptake into the reticuloendothelial system ("RES"), metab. or elimination, then tested in vivo.

IT Drug delivery systems
(***oral*** ; formulation arrays for screening)

IT 110-82-7D, Cyclohexane, ***benzofuran*** derivs. complexes 112-80-1, Oleic acid, biological studies 121-54-0, Benzethonium chloride 151-21-3, Sodium dodecyl sulfate, biological studies 271-89-6D, ***Benzofuran*** , derivs., cyclohexane complexes 3287-99-8D, Benzylammonium chloride, trialkyl derivs. 6106-24-7, Sodium tartrate dihydrate 7585-39-9, .beta.-Cyclodextrin 8044-71-1, Cetrimide 9000-01-5, Gum arabic 9002-89-5, Polyvinyl alcohol 9002-92-0, BRIJ 35 9004-98-2, BRIJ 97 9004-99-3, Polyethylene glycol stearate 9005-65-6, ***TWEEN*** 80 25322-68-3, Polyethylene glycol 106392-12-5, ***POLOXAMER*** 237
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation arrays for screening)

=> d his

(FILE 'HOME' ENTERED AT 12:24:52 ON 12 JUN 2001)

FILE 'REGISTRY' ENTERED AT 12:25:07 ON 12 JUN 2001
L1 1 S AMIODARONE/CN
L2 1 S DRONEDARONE/CN

FILE 'MEDLINE, EMBASE, EMBAL, CA, CAPLUS, BIOSIS' ENTERED AT 12:26:09 ON 12 JUN 2001
L3 21282 S L1 OR L2
L4 37729 S CORDARONE OR AMIODARONE OR BENZOFURAN OR DRONEDARONE
L5 37780 S L3 OR L4
L6 22946 S ANIONIC SURFACTANT
L7 45179 S POLOXAMER? OR POLYETHYOXYLATED CASTOR OIL? OR ETHOXYLATED POL
L8 66 S L5 AND L7
L9 33 DUP REM L8 (33 DUPLICATES REMOVED)
L10 1486690 S ORAL OR TABLET OR CAPSULE OR GELATIN OR PILL
L11 4 S L9 AND L10

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	87.32	98.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.68	-1.68

STN INTERNATIONAL LOGOFF AT 12:42:10 ON 12 JUN 2001